PROTAC AR-V7 degrader-1

Target: Targets androgen receptor variants, including full-length AR and AR-V7 for experimental targeted protein degradation studies.

Binding Site: Binds the AR ligand-binding or variant-associated domain and E3 ligase ligand site to support productive ternary complex formation.

Mechanism of Action: PROTAC AR-V7 degrader-1 is designed for use in PROTAC or targeted protein degradation experiments directed toward androgen receptor variants, including full-length AR and AR-V7. The bifunctional molecule links a target-recognition element to cereblon, promoting proximity between the protein of interest and ubiquitination machinery. Productive ternary-complex formation can drive polyubiquitination and proteasome-dependent target depletion, allowing researchers to compare pharmacological inhibition with protein removal. It is suitable for evaluating degradation potency, kinetics, pathway selectivity, and downstream signaling consequences in engineered or disease-relevant cellular models.

• PROTAC-Mediated AR-V7 Degradation: This PROTAC compound specifically targets and promotes the degradation of the androgen receptor variant 7 (AR-V7), a critical player in castration-resistant prostate cancer. Researchers can utilize this tool to study AR-V7's role in cancer progression and resistance mechanisms, offering insights into potential therapeutic strategies.

• Targeted Protein Degradation in Oncology: By facilitating the selective degradation of AR-V7, this PROTAC enables the exploration of targeted protein degradation as a strategy to overcome drug resistance in prostate cancer. It serves as a valuable asset for investigating the impact of AR-V7 depletion on tumor cell survival and proliferation.

• Mechanistic Studies of AR-V7: This PROTAC provides a robust means to dissect the molecular pathways involving AR-V7. Researchers can employ this compound to elucidate the downstream effects of AR-V7 degradation, aiding in the identification of novel biomarkers and therapeutic targets in cancer research.

• PROTAC-Driven Functional Genomics: Leveraging this PROTAC allows for functional genomics studies focusing on AR-V7. By inducing targeted degradation, scientists can assess gene expression changes and pathway alterations, advancing the understanding of AR-V7's comprehensive role in cellular physiology and pathophysiology.